Amneal Pharmaceuticals Inc (AMRX) Given Consensus Recommendation of “Hold” by Analysts

Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) have been given an average rating of “Hold” by the thirteen brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.00.

Several equities analysts recently commented on AMRX shares. Cantor Fitzgerald reaffirmed a “buy” rating and set a $35.00 target price on shares of Amneal Pharmaceuticals in a report on Thursday, February 28th. Zacks Investment Research lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 8th. ValuEngine lowered shares of Amneal Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, January 10th. Leerink Swann reaffirmed an “outperform” rating and set a $19.00 target price (down previously from $25.00) on shares of Amneal Pharmaceuticals in a report on Thursday, January 3rd. Finally, Morgan Stanley lowered shares of Amneal Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $24.00 to $18.00 in a report on Friday, December 14th.

In other Amneal Pharmaceuticals news, Director Peter R. Terreri sold 23,345 shares of the stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $12.39, for a total transaction of $289,244.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Paul Bisaro purchased 17,000 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were purchased at an average cost of $11.97 per share, with a total value of $203,490.00. The disclosure for this purchase can be found here. Corporate insiders own 3.20% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC boosted its position in Amneal Pharmaceuticals by 13.9% during the 4th quarter. Geode Capital Management LLC now owns 889,980 shares of the company’s stock valued at $12,041,000 after buying an additional 108,455 shares during the period. Norges Bank purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth about $18,243,000. Amalgamated Bank purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth about $174,000. Legal & General Group Plc lifted its position in shares of Amneal Pharmaceuticals by 5.5% in the 4th quarter. Legal & General Group Plc now owns 34,505 shares of the company’s stock worth $467,000 after purchasing an additional 1,810 shares during the period. Finally, Metropolitan Life Insurance Co. NY lifted its position in shares of Amneal Pharmaceuticals by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 28,627 shares of the company’s stock worth $387,000 after purchasing an additional 22,358 shares during the period. 38.90% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE:AMRX opened at $14.17 on Friday. The firm has a market capitalization of $4.25 billion, a PE ratio of 14.92, a P/E/G ratio of 0.65 and a beta of 1.37. Amneal Pharmaceuticals has a one year low of $11.63 and a one year high of $24.48. The company has a debt-to-equity ratio of 2.98, a quick ratio of 1.50 and a current ratio of 2.32.

Amneal Pharmaceuticals (NYSE:AMRX) last released its earnings results on Thursday, February 28th. The company reported $0.32 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.06. Amneal Pharmaceuticals had a negative net margin of 9.92% and a positive return on equity of 16.46%. The company had revenue of $497.53 million for the quarter, compared to analyst estimates of $478.06 million. Research analysts expect that Amneal Pharmaceuticals will post 0.98 EPS for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations.

Featured Article: How Do Investors Open a Backdoor Roth IRA?

Analyst Recommendations for Amneal Pharmaceuticals (NYSE:AMRX)

Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.